A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

A Randomized, Phase II Study of ivonescimab or cadonilimab or penpulimab in Combination With Cisplatin and Nab-paclitaxel in Patients With locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection. This proposed study will evaluate the efficacy and safety of preoperative administration of ivonescimab or cadonilimab or penpulimab combined with chemotherapy in HNSCC who are eligible for resection.

Trial Details

NCT ID
NCT06444009
Phase
PHASE2
Sponsor
Lei Liu
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Ivonescimab combined with TP
  • Cadonilimab combined with TP
  • Penpulimab combined with TP
Locations (sample)
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Males and females； Age：18 to 75 years.
  • Histologically or cytologically confirmed head and neck squamous cell carcinoma (HNSCC).
  • Patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →